Veracyte is a molecular diagnostics company that focuses on developing and delivering genomic diagnostic tests to improve patient outcomes. The company was founded in 2006 by Bonnie Anderson and Jesse Salk with the goal of leveraging advanced genomic technology to revolutionize diagnostic testing for patients with suspected cancer or other diseases. Veracyte is headquartered in South San Francisco, California, USA.
Veracyte's mission is to provide non-invasive, clinically meaningful diagnostic tests that help physicians avoid unnecessary surgeries and other invasive procedures. They achieve this through their innovative genomic tests that analyze the RNA sequencing of patient samples, allowing for more accurate and reliable diagnoses.
One of Veracyte's flagship products is the "Afirma Genomic Sequencing Classifier" used to assess thyroid nodules. This test helps to determine if a nodule is benign and can reduce the number of unnecessary surgeries. They also offer the "Percepta Bronchial Genomic Classifier," used for lung cancer diagnosis, and the "Envisia Genomic Classifier," used for interstitial lung diseases.
The company has received numerous accolades and recognition for its contributions to healthcare, including being named one of the World's Most Innovative Companies by Fast Company in 2020. Veracyte continues to be at the forefront of advancing genomic testing to enhance patient care and improve diagnostic accuracy in various diseases, making it a significant player in the molecular diagnostics industry.